Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.68 ▼ -0.04
(-5.78%)
MKT CAP: $5.2M • VOL: 62.7K
52W L $1 52W H $5
CELZ // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $6.0K | $11.0K | $9.0K |
| YoY Revenue Growth % | -45.5% | +22.2% | — |
| Gross Profit | $3.8K | $6.6K | — |
| Gross Margin % | 63.4% | 60.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$6.1M | -$5.7M | -$5.6M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$6.0M | -$5.5M | -$5.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.9M | -$5.3M | -$8.0M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$5.9M | -$5.3M | -$8.0M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $7.5M | $6.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CELZ.